BioGeometry closes Series A rounds totaling over $100 million for molecular and cellular world models

BioGeometry, a Beijing-based AI-native biopharma company, announced its Series A+ financing, taking Series A funding above US$100 million, to develop its GeoFlow molecular and GeoCell cellular world models and automated labs (October 28, 2026).